| 引用本文: |
王立春,王定国,林天东.国医大师林天东治疗反流性食管炎的用药规律与核心药对的潜在机制研究[J].湖南中医药大学学报,2022,42(9):1493-1501[点击复制] |
|
| |
|
|
| 本文已被：浏览 1201次 下载 419次 |
| 国医大师林天东治疗反流性食管炎的用药规律与核心药对的潜在机制研究 |
| 王立春,王定国,林天东 |
| (海南省中医院, 海南 海口 570203) |
| 摘要: |
| 目的 探讨国医大师林天东治疗反流性食管炎(reflux esophagitis,RE)的用药规律与核心药对的潜在作用机制。方法 采集2020年1月至2022年1月于海南省中医院国医大师林天东门诊就诊的RE处方，建立处方数据库。采用用药频数统计及关联规则算法挖掘林天东教授治疗RE的核心药对，并利用网络药理学方法对核心药对的作用机制进行分析。结果 共有249张处方纳入研究，半夏-沉香为核心药对；半夏-沉香药对中口服生物利用度≥40%的主要活性成分为钓樟烷、环(酪氨酸-苯丙氨酸)二肽、槲皮素、次黄嘌呤核苷、豆甾醇、儿茶素、12,13-环氧-9-羟基十九碳-7，10-二烯酸、新木姜子碱、黄芩苷；半夏-沉香药对治疗RE核心靶点8个，重要通路10条。结论 国医大师林天东临床治疗RE的核心药对半夏-沉香可能通过调节机体免疫、抗炎、抗氧化、保护胃黏膜、抗肿瘤等反应发挥治疗作用。 |
| 关键词: 反流性食管炎 数据挖掘 网络药理学 半夏厚朴汤 半夏 沉香 林天东 |
| DOI：10.3969/j.issn.1674-070X.2022.09.012 |
| 投稿时间：2022-05-12 |
| 基金项目:国家中医药管理局中医药传承与创新"百千万"人才工程(岐黄工程)(琼财社[2018]186号);海南省卫生健康行业科研项目(21A200154);海南省重大科技计划项目(ZDKJ2021034)。 |
|
| Medication rule and potential mechanism of the core drug pairs in treating reflux esophagitis by LIN Tiandong,the national master of TCM |
| WANG Lichun,WANG Dingguo,LIN Tiandong |
| (Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou, Hainan 570203, China) |
| Abstract: |
| Objective To explore the medication rule and the potential mechanism of core drug pair of LIN Tiandong, the national master of TCM in the treatment of reflux esophagitis (RE). Methods Prescriptions of RE treated in professor LIN Tiandong's clinic of Hainan Provincial Hospital of Traditional Chinese Medicine from January 2020 to January 2022 were collected to establish a prescription database. The drug frequency statistics and association rule algorithm were used to explore the core drug pairs of professor LIN Tiandong in the treatment of RE, and the mechanism of action of the core drug pairs was analyzed by network pharmacology. Results A total of 249 prescriptions were included in the study. Banxia (Pinelliae Rhizoma)-Chenxiang (Aquilariae Lignum Resinatum) was identified as the core drug pair. The main active components of OB≥40% in Banxia (Pinelliae Rhizoma)-Chenxiang (Aquilariae Lignum Resinatum) were linderane, (3S,6S)-3-(benzyl)-6-(4-hydroxybenzyl) piperazine-2,5-quinone, quercetin, hypoxanthine-9-beta-D-ribofuranoside, stigmasterol, nubigenol, 12, 13-epoxy-9-hydroxynonadeca-7, 10-dienoic acid, norboldine, and baicalin. There were 8 core targets and 10 important pathways for the treatment of RE by Banxia (Pinelliae Rhizoma)-Chenxiang (Aquilariae Lignum Resinatum). Conclusion The core drug of Banxia (Pinelliae Rhizoma)-Chenxiang (Aquilariae Lignum Resinatum) of LIN Tiandong (the national master of TCM)'s clinical treatment of RE may play a therapeutic role through regulating immune, anti-inflammatory, antioxidant, gastric mucosa protection, anti-tumor and other reactions. |
| Key words: reflux esophagitis data mining network pharmacology Banxia Houpu Decoction Banxia (Pinelliae Rhizoma) Chenxiang (Aquilariae Lignum Resinatum) LIN Tiandong |
|
二维码（扫一下试试看！） |
|
|
|
|
